-
Hyponatremia is frequently seen in patients with left ventricular failure and has recently been shown to be associated with right ventricular dysfunction and worse outcomes in patients with pulmonary hypertension.
-
In this issue: Statins and liver function; dosing timing for thyroxine; rivaroxaban for VTE, DVT, and stroke; echinacea and the common cold; and FDA actions.
-
-
A long-time patient, who is a 56-year-old male, arrives for his annual exam complaining of excessive thirst, frequent urination, unplanned weight gain, and fatigue. His blood pressure, which was borderline hypertensive last year, is now 160/95. He reports no change in diet, job responsibilities, or family life. This year, you have added another screening to the standard vital signs.
-
-
A 74-year retired veterinarian presents to the emergency department (ED) with shortness of breath. He was recently diagnosed with diffuse large-cell lymphoma with prominent abdominal lymphadenopathy and positive bone marrow and has been treated with two cycles of R-CHOP.
-
The U.S. Food and Drug Administration (FDA) has recently approved denosumab for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
-
Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
-
A trial undertaken by EORTC was designed to determine if neoadjuvant chemotherapy would be successful in the absence of post-surgical chemotherapy in enhancing overall survival in patients with locally advanced gastric cancer. The trial did not accrue sufficient numbers of patients to demonstrate a survival benefit. However, presurgical chemotherapy was associated with a higher rate of complete resection and fewer positive lymph nodes, features that suggest progression-free and overall survival might be favorably affected.
-
In a retrospective review of consecutive patients with colon cancer, the presence of diabetes mellitus was found to confer negative prognostic information with regard to overall, and cancer-specific, survival. Notably, it was in patients with stage II disease that the presence of diabetes was of most importance.
